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Giuseppe De Luca, MD, Grazia Ucci, MD, Ettore Cassetti, MD, Paolo Marino, MD
Novara, Italy
Objectives The aim of the study was to perform a meta-analysis of randomized trials (RTs) comparing abciximab versus
small molecules (eptifibatide and tirofiban) in primary angioplasty (PPCI) for ST-segment elevation myocardial
infarction (STEMI).
Background Abciximab has been shown to provide significant benefits in PPCI for STEMI. However, small molecules repre-
sent an attractive strategy due to the reversibility of the inhibition of platelet aggregation and the lower costs.
Methods We obtained results from RTs comparing abciximab versus small molecules in PPCI. The literature was scanned
by searches of electronic databases (MEDLINE and CENTRAL) up to October 2008. The following key words were
used: RT, myocardial infarction, reperfusion, primary angioplasty, glycoprotein IIb/IIIa inhibitors, abciximab, tiro-
fiban, and eptifibatide. Concerning tirofiban, we only included trials or groups of patients with high-dose bolus
and infusion. The primary end point was 30-day mortality. Secondary end points were 30-day reinfarction, post-
procedural Thrombolysis In Myocardial Infarction (TIMI) flow grade 3, and ST-segment resolution.
Results A total of 6 RTs were included in the meta-analysis, involving 2,197 patients (1,082 randomized to abciximab
and 1,115 to small molecules [high-dose tirofiban in 5 trials and eptifibatide in 1 trial]). Abciximab did not im-
prove post-procedural TIMI flow grade 3 (89.8% vs. 89.1%, p  0.72) or ST-segment resolution (67.8% vs.
68.2%, p  0.66). Abciximab did not reduce 30-day mortality (2.2% vs. 2.0%, p  0.66) or reinfarction (1.2% vs.
1.2%, p  0.88), nor was there any difference in major bleeding complications (1.3% vs. 1.9%, p  0.27).
Conclusions This meta-analysis shows among STEMI patients undergoing PPCI similar results between abciximab and small
molecules in terms of angiographic, electrocardiographic, and clinical outcome. (J Am Coll Cardiol 2009;53:
1668–73) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.053m
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mrimary angioplasty has been shown to reduce mortality as
ompared with thrombolysis, due to the ability to restore
hrombolysis In Myocardial Infarction (TIMI) flow grade
more rapidly in the vast majority of patients (1). However,
uboptimal reperfusion may be observed in a relatively large
roportion of patients despite TIMI flow grade 3, mainly
ue to no-reflow phenomenon and distal embolization (2).
arge interest has been focused in the last years on the
djunctive administration of glycoprotein (GP) IIb/IIIa
nhibitors to improve perfusion and mortality. Previous
rom the Division of Cardiology, “Maggiore della Carità” Hospital, Eastern
iedmont University “A. Avogadro,” Novara, Italy. Dr. De Luca has received lecture
ees from Eli Lilly, Merck Sharp, and Dohme.a
Manuscript received October 30, 2008; revised manuscript received December 17,
008, accepted January 7, 2009.eta-analyses of randomized trials (3,4) have shown signif-
cant benefits in mortality and reinfarction with abciximab
dministration as compared with placebo. However, grow-
See page 1674
ng interests have been observed on the role of small
olecules (eptifibatide and tirofiban). In fact, due to the
eversibility of the inhibition of platelet aggregation and the
ower costs, they represent a very attractive strategy. Several
andomized trials have so far been conducted, but all of
hem were underpowered to detect any difference in terms
f hard clinical end points such as death and reinfarction.
hus, the aim of the current study was to perform a
eta-analysis of randomized trials to evaluate whether
bciximab may offer benefits in mortality as compared
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May 5, 2009:1668–73 Abciximab Versus Small Molecules in Primary PCIith small molecules among ST-segment elevation myocar-
ial infarction (STEMI) patients undergoing primary
ngioplasty.
ethods
ligibility and search strategy. We obtained results from
ll randomized trials evaluating the benefits of adjunctive
P IIb/IIIa inhibitors among STEMI patients undergoing
rimary angioplasty. The literature was scanned by formal
earches of electronic databases (MEDLINE and
ENTRAL), the scientific session abstracts in Circulation,
ournal of the American College of Cardiology, European
eart Journal, and American Journal of Cardiology from
anuary 1990 to October 2008. Furthermore, oral pre-
entations and/or expert slide presentations were in-
luded (searched on the TCT, EuroPCR, ACC, AHA,
nd ESC websites from January 2002 to October 2008). The
ollowing key words were used: randomized trial, myocardial
nfarction, reperfusion, primary angioplasty, GP IIb/IIIa in-
ibitors, abciximab, tirofiban, and eptifibatide.
Inclusion criteria were: randomized treatment alloca-
ion and availability of complete clinical data. Exclusion
riteria were: follow-up data in less than 90% of patients
nd ongoing studies or irretrievable data. No language
estrictions were enforced.
ata extraction and validity assessment. Data were inde-
endently abstracted by 2 investigators. In case of incomplete
r unclear data, authors, where possible, were contacted.
isagreements were resolved by consensus. Data were man-
ged according to the intention-to-treat principle.
utcome. Primary end point was 30-day mortality. Second-
ry end points were reinfarction at 30 days, post-procedural
IMI flow grade 3 and ST-segment resolution. Major bleed-
ng complications were assessed as safety end point.
ata analysis. Statistical analysis was performed using the
eview Manager 4.27 and SPSS 11.0 statistical package
SPSS Inc., Chicago, Illinois). Odds ratio (OR) and 95%
onfidence intervals (CIs) were used as summary statistics.
he pooled OR was calculated by using a fixed-effect model
ith the Mantel-Haenszel method. The DerSimonian and
aird random effect models were additionally applied to
alculate pooled OR in case of significant heterogeneity
cross studies. Between-study heterogeneity was analyzed
y means of: I2  [(Q  df)/Q]  100%, where Q is the
hi-square statistic, and df is its degrees of freedom. The
otential publication bias was examined by constructing a
funnel plot,” in which the standard error of the ln OR was
lotted against the OR (30-day mortality). The study was
erformed in compliance with the Quality of Reporting of
eta-Analyses (QUORUM) guidelines (5).
esults
ligible studies. Of the 865 potentially relevant articles
nitially screened, a total of 7 trials were initially identified
6–12). One trial was excluded because no data were availablen clinical outcome (the first au-
hor was contacted) (9). Thus, a
otal of 6 trials were finally in-
luded in the meta-analysis (Fig.
), involving 2,197 patients
1,082 or 49.2% randomized to
bciximab and 1,115 or 50.8%
andomized to small mole-
ules). Characteristics of the in-
luded trials are shown in Table
. No disagreement was ob-
erved in data collection. In the
TRATEGY (Tirofiban and
irolimus-Eluting Stent vs Abciximab and Bare-Metal
tent for Acute Myocardial Infarction: A Randomized
rial) (8) and MULTISTRATEGY (Multicentre Evalua-
ion of Single High-Dose Bolus Tirofiban vs Abciximab
ith Sirolimus-Eluting Stent or Bare Metal Stent in Acute
yocardial Infarction) (10) trials, patients were additionally
andomized to bare-metal stents and sirolimus-eluting
tents. High-dose tirofiban was used in 5 studies (6–8,10,11),
hereas eptifibatide was tested in the EVA-AMI (Eptifibatide
ersus Abciximab in Primary PCI for Acute ST elevation
yocardial Infarction) trial (12). In the study by Ernst et al.
6), patients were randomized to placebo, abciximab, high-dose
irofiban, and tirofiban at standard dose, but only abciximab and
igh-dose tirofiban patients were included in our study.
linical end points. As shown in Figure 2, abciximab did
ot reduce either 30-day mortality (2.2% vs. 2.0%, OR: 1.14,
5%CI: 0.64 to 2.04, p 0.66, p heterogeneity [phet] 0.62) or
einfarction (1.2% vs. 1.2%, OR: 0.94, 95% CI: 0.44 to 2.04,
 0.88, phet 0.2), as compared with small molecules. As
hown in Figure 3, no publication bias was observed.
ngiographic and electrocardiographic end points. As
hown in Figure 4, abciximab did not improve either post-
rocedural TIMI flow grade 3 (89.8% vs. 89.1%, OR: 1.03,
5% CI: 0.78 to 1.36, p  0.72, phet  0.62) or ST-segment
Abbreviations
and Acronyms
CI  confidence interval
GP  glycoprotein
OR  odds ratio
phet  p heterogeneity
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
865 potentially relevant citations identified
and screened for retrieval
858 citations excluded because not relevant
to the systemic overview
6 RCTs finally included
in the meta-analysis
1 trial was excluded because of 
absence of data on clinical outcome
7 RCTs selected
Figure 1 Flow Diagram of the Systematic Overview Process
RCT  randomized controlled trial.
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Table 1 Characteristics of Randomized Trials Included in the Meta-Analysis
Study (Ref. #) Period N
Administration
of Study Drug
Study Drug Design
(Number of Patients) Primary End Point
Definition of Major Bleeding
Complications
Ernst et al. (6) 2002–2003 59 Peri-procedural Abciximab (n  30) or
high-dose tirofiban (n  29)
Platelet aggregation
inhibition
Blood transfusion or surgery,
intracranial or peritoneal
hemorrhage
Danzi et al. (7) 2002 100 Peri-procedural Abciximab (n  50) vs.
high-dose tirofiban (n  50)
Wall motion score index NA
MULTISTRATEGY (10) 2004–2007 744 Pre-procedural Abciximab-SES (n  186),
abciximab-BMS (n  186),
high-dose tirofiban-SES (n  186),
high-dose tirofiban-BMS (n  186)
ST-segment resolution TIMI major bleeding
STRATEGY (8) 2003–2004 175 Pre-procedural Abciximab-BMS (n  88) vs.
high-dose tirofiban-SES (n  87)
8-month combined death,
reinfarction, stroke,
and binary restenosis
TIMI major bleeding
FATA (11) 2005–2007 692 Pre- and peri-
procedural
Abciximab (n  341) vs.
high-dose tirofiban (n  351)
ST-segment resolution Intracranial hemorrhage, bleeding
requiring surgery or transfusion,
Hb drop 5 g/l
EVA-AMI (12) 2006–2007 429 Peri-procedural Abciximab (n  203) vs.
eptifibatide (n  226)
ST-segment resolution NA
bciximab dose: 0.25 mg/kg intravenous bolus followed by 12-h infusion at 0.125 mg kg1 min1; eptifibatide dose: 2 boluses of 180 mg/kg intravenous 10 min apart, then 2.0 mg kg1 min1 infusion;
igh-dose tirofiban: 25 g/kg bolus and 0.15 g/kg/min infusion over 18 to 24 h.
BMS  bare-metal stent(s); EVA-AMI  Eptifibatide Versus Abciximab in Primary PCI for Acute ST elevation Myocardial Infarction trial; FATA  Facilitated Angioplasty with Tirofiban or Abciximab trial;
b  hemoglobin; MULTISTRATEGY  Multicentre Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction study;
A not available; Pre-procedural before stent insertion; Peri-procedural after initial angiography; SES sirolimus-eluting stent(s); STRATEGY Tirofiban and Sirolimus-Eluting Stent Versus Abciximab
nd Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial; TIMI  Thrombolysis In Myocardial Infarction.DEATH                                                           
xif( ROthgieW)dexif( ROseluceloMllamSbamixicbAydutS ed)
IC %59%IC %59N/nN/n
Favors Abciximab Favors Small Molecules
DANZI               0/50           0/50        Not estimable
ERNST               0/30           1/29        7.01 0.31 [0.01, 7.96]        
EVA-AMI              7/201          8/226       33.95 0.98 [0.35, 2.76]        
FATA                5/341          7/351       31.75 0.73 [0.23, 2.33]        
MULTISTRATEGY      9/372          4/372       18.23 2.28 [0.70, 7.47]        
STRATEGY            3/88           2/87        9.07 1.50 [0.24, 9.20]        
Total (95% CI) 24/1082         22/1115 100.00 1.14 [0.64, 2.04]
Test for heterogeneity: Chi² = 2.66, df = 4 (P = 0.62), I² = 0%
Test for overall effect: Z = 0.44 (P = 0.66)
0.1 0.2 0.5 1 2 5 10
Reinfarction
xif( ROthgieW)dexif( ROseluceloMllamSbamixicbAydutS ed)
IC %59%IC %59N/nN/n
Favors Abciximab Favors Small Molecules
ERNST               0/30              0/29        Not estimable
EVA-AMI              3/201             0/226       3.49 7.99 [0.41, 155.58]      
FATA                1/341             2/351       14.82 0.51 [0.05, 5.69]        
MULTISTRATEGY      5/372            10/372       74.37 0.49 [0.17, 1.46]        
STRATEGY            3/88              1/87        7.32 3.04 [0.31, 29.76]       
Total (95% CI) 12/1032          13/1065 100.00 0.94 [0.44, 2.04]
Test for heterogeneity: Chi² = 4.62, df = 3 (P = 0.20), I² = 35.0%
Test for overall effect: Z = 0.15 (P = 0.88)
0.1 0.2 0.5 1 2 5 10
Figure 2 Clinical Outcome
Comparison between abciximab and small molecules in terms of mortality (top) and reinfarction (bottom) at 30-day follow-up, with odds ratios (ORs) and 95% confi-
dence intervals (CIs). The size of the data markers (squares) is approximately proportional to the statistical weight of each trial. EVA-AMI  Eptifibatide Versus Abcix-
imab in Primary PCI for Acute ST elevation Myocardial Infarction trial; FATA  Facilitated Angioplasty with Tirofiban or Abciximab trial; MULTISTRATEGY  Multicentre
Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction study; STRATEGY 
Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial.
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May 5, 2009:1668–73 Abciximab Versus Small Molecules in Primary PCIesolution (67.8% vs. 68.2%, OR: 0.96, 95% CI: 0.78 to 1.17,
 0.66, phet  0.3), as compared with small molecules.
leeding complications. As shown in Figure 5, abciximab
as associated with slightly lower rates of major bleeding
0.1 0.2 0.5 1 2 5 10
0.0
0.4
0.8
1.2
1.6
SE(log OR)
OR (fixed)
Figure 3 Funnel Plot of All Studies
Included in the Meta-Analysis
The standard error (SE) of the ln odds ratio (OR) was plotted against the OR for
mortality. No skewed distribution was observed, suggesting no publication
bias. The study by Danzi et al. (7) is not represented due to the absence of
death at follow-up in both groups.
ST-resolution
Study Abciximab Small Molecules
N/nN/n
Favors Sm
Postprocedural TIMI 3                     
Study Abciximab Small Molecules
N/nN/n
Favors Sma
EVA-AMI              95/200           113/225      
FATA                236/335           231/346      
MULTISTRATEGY      302/361           308/361      
STRATEGY            34/88             43/87       
Total (95% CI) 667/984           695/1019
Test for heterogeneity: Chi² = 3.63, df = 3 (P = 0.30), I² = 17.4%
Test for overall effect: Z = 0.44 (P = 0.66)
0.1 0.
DANZI               43/50           44/50        
ERNST               26/28           24/28        
EVA-AMI              171/203          186/226       
FATA                304/341          318/351       
MULTISTRATEGY      346/372          338/372       
STRATEGY            82/88            84/87        
Total (95% CI) 972/1082        994/1114
Test for heterogeneity: Chi² = 3.50, df = 5 (P = 0.62), I² = 0%
Test for overall effect: Z = 0.36 (P = 0.72)
0.1 0
Figure 4 TIMI Flow Grade 3 and ST-Segment Resolution
Comparison between abciximab and small molecules in terms of post-procedural T
ST-segment resolution (bottom), with ORs and 95% CIs. The size of the data marke
ST-segment resolution was defined as ST-segment resolution 70%, except in the MUomplications (1.3% vs. 1.9%, OR: 0.69, 95% CI: 0.36 to
.34, p  0.27, phet  0.44).
iscussion
he main finding of this meta-analysis is that abciximab
oes not provide significant benefits in post-procedural
IMI flow grade 3, post-procedural ST-segment resolu-
ion, mortality, and reinfarction at 30 days follow-up, with
lightly lower rates of major bleeding complications as
ompared with small molecules.
Several randomized trials have shown that primary an-
ioplasty is superior to thrombolysis. However, although
rimary angioplasty is able to restore TIMI flow grade 3 in
he vast majority of patients, a relatively large proportion of
atients experience poor reperfusion (2). In the last years,
rowing interests have been focused on the role of distal
mbolization as a major determinant of poor reperfusion
2). GP IIb/IIIa inhibitors are the most powerful class of
ntiplatelet therapies. A recent meta-analysis has shown
ignificant benefits in mortality and reinfarction with
djunctive abciximab administration (3). The benefits in
ortality have been confirmed at long-term follow-up (4).
owever, larger interests have been focused in the last years
n the role of small molecules (eptifibatide and tirofiban). In
OR (fixed) Weight OR (fixed)
IC %59%IC %59
lecules Favors Abciximab
                          
OR (fixed) Weight OR (fixed)
IC %59%IC %59
cules Favors Abciximab
27.94 0.90 [0.61, 1.31]        
33.60 1.19 [0.86, 1.64]        
25.18 0.88 [0.59, 1.32]        
13.28 0.64 [0.35, 1.17]        
100.00 0.96 [0.78, 1.17]
.5 1 2 5 10
6.22 0.84 [0.26, 2.70]        
1.73 2.17 [0.36, 12.92]       
28.03 1.15 [0.69, 1.91]        
34.35 0.85 [0.52, 1.40]        
23.86 1.34 [0.79, 2.28]        
5.82 0.49 [0.12, 2.02]        
100.00 1.05 [0.80, 1.39]
0.5 1 2 5 10
olysis In Myocardial Infarction (TIMI) flow grade 3 (top) and complete
uares) is approximately proportional to the statistical weight of each trial. Complete
ATEGY trial, where a threshold of 50% was used. Abbreviations as in Figure 2.all Mo
          
ll Mole
 
 
 
 
2 0
.2
hromb
rs (sq
LTISTR
f
m
r
o
i
e
c
s
3
s
t
c
c
S
(
(
d
t
S
r
a
p
m
o
l
(
5
t
f
i
b
n
a
c

w
p
a
t
s
a
b
i
S
d
a
G
s
w
m
m
l
w
o
p
t
t
i
w
t
t
t
r
r
C
T
g
a
1672 De Luca et al. JACC Vol. 53, No. 18, 2009
Abciximab Versus Small Molecules in Primary PCI May 5, 2009:1668–73act, even though the antiplatelet effects of abciximab
ay be reversed by platelet infusion, small molecules
epresent a very attractive strategy due to the reversibility
f the inhibition of platelet aggregation at the end of the
nfusion and the lower costs. A previous large trial in
lective or urgent percutaneous coronary angioplasty
omparing abciximab and standard dose of tirofiban has
hown a significant difference in clinical outcome at
0-day but not 180-day follow-up (13,14). However, in
mall randomized trials (6,8), it was shown that high-dose
irofiban was associated with a better platelet inhibition as
ompared with abciximab. Several randomized trials have
ompared abciximab to high-dose tirofiban or eptifibatide in
TEMI patients undergoing primary angioplasty
6–8,10,11). The first trial was conducted by Danzi et al.
7), who in a small cohort of patients did not observe any
ifference in clinical outcome and in left ventricular func-
ional recovery. In the STRATEGY (8) and MULTI-
TRATEGY (10) trials, no difference in death and/or
einfarction was observed between high-dose tirofiban
nd abciximab. In the EVA-AMI trial (12), 400 STEMI
atients were randomly assigned to periprocedural ad-
inistration of eptifibatide or abciximab, with similar
utcome observed between the 2 molecules. The major
imitation of the study is that the primary end point
ST-segment resolution at 60 to 90 min) was available in only
0% of patients. Even though the recent FATA (Facili-
ated Angioplasty with Tirofiban or Abciximab) trial
ailed to show noninferiority of tirofiban versus abcix-
mab, the authors found a similar clinical outcome
etween the 2 groups of patients (11).
In our meta-analysis, including 2,197 patients, we did
ot observe any difference in clinical outcome between
bciximab and small molecules. According to current
osts of treatment with GP IIb/IIIa inhibitors (abciximab
1,542€; tirofiban  358€; eptifibatide  195€), we
seluceloMllamSbamixicbAydutS
N/nN/n
Favors
Major Bleeding Complications
DANZI               0/50             0/50      
ERNST               0/30             2/29      
EVA-AMI              0/201            4/226     
FATA                6/341            5/351     
MULTISTRATEGY      6/372            9/372     
STRATEGY            2/88             1/87      
Total (95% CI) 14/1082          21/1115
Test for heterogeneity: Chi² = 3.73, df = 4 (P = 0.44), I² = 0%
Test for overall effect: Z = 1.09 (P = 0.27)
0.1
Figure 5 Major Bleeding Complications
Comparison between abciximab and small molecules in terms of major bleeding c
The size of the data markers (squares) is approximately proportional to the statistould save a total of 1,184.00€ and 1,347.00€ per each datient treated with tirofiban or eptifibatide, respectively,
s compared with abciximab. Future large randomized
rials are certainly needed to compare abciximab versus
mall molecules in high-risk STEMI patients. In fact, in
previous analysis, we observed a significant relationship
etween risk profile and benefits from abciximab admin-
stration (15).
tudy limitations. The availability of individual patients’
ata would have further improved the results of our meta-
nalysis. We analyzed short-term outcomes, whereas some
P IIb/IIIa inhibitor studies have demonstrated increased
urvival benefits with longer follow-up (4). Furthermore, if
e would consider as clinically relevant a reduction in
ortality of 1% from the mortality (2%) observed with small
olecules, with a statistical power of 80% and significance
evel (alpha) of 0.05, a total of 2,514 patients per group
ould have been needed to show such a difference. Thus,
ur study population and analysis was statistically under-
owered (60%). Data on the interval between administra-
ion of the drug and PCI were not available from many
rials. However, in the vast majority of them, GP IIb/IIIa
nhibitors were started after initial angiography, and thus
ith a presumably very short interval between adminis-
ration of the drug and percutaneous coronary interven-
ion. Finally, the limits in the evaluation and interpreta-
ion of publication bias due to the restricted number of
andomized trials included in our meta-analysis must be
ecognized.
onclusions
his meta-analysis shows among STEMI patients under-
oing primary angioplasty similar results between abciximab
nd small molecules in terms of angiographic, electrocar-
xif( ROthgieW)dexif( RO ed)
IC %59%IC %59
imab Favors Small Molecules
Not estimable
11.68 0.18 [0.01, 3.92]     
19.75 0.12 [0.01, 2.29]     
22.62 1.24 [0.37, 4.10]     
41.37 0.66 [0.23, 1.88]     
4.59 2.00 [0.18, 22.47]    
100.00 0.69 [0.36, 1.34]
0.5 1 2 5 10
ations, with ORs and 95% CIs.
eight of each trial. Abbreviations as in Figure 2.Abcix
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ical wiographic, and clinical outcome.
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